What is MARIMED INC's earnings per share (EPS)?

MARIMED INC (MRMD) reported diluted earnings per share of -$0.04 for fiscal year 2025. This represents a -33.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MARIMED INC (MRMD) Financials

MRMD

Trailing 12 months to June 30, 2026

Revenue $163.8M +4.5% YoY

Net Income -$15.0M +9.0% YoY

EPS (Diluted) -$0.04 -33.3% YoY

Free Cash Flow $8.0M +461.0% YoY

Market Cap $23.0M as of Oct 19, 2026

Price / Sales 0.1x on $163.8M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 0.5x on $43.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MRMD SEC filings page.

MARIMED INC (MRMD) reported $163.8M in revenue over the twelve months to Jun 30, 2026, up 4.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MRMD FY2025 2026-10-03

Revenue has nearly stalled while margins keep shrinking, leaving MariMed increasingly dependent on balance-sheet financing and cash discipline.

By FY2025, gross margin compression had reduced the economics of each sale: gross margin was 36.2% even as revenue reached $159.8M. Operating cash flow stayed positive at $7.7M while net income was a loss of $14.5M; the gap indicates noncash charges and working-capital movements, not cash profitability.

Free cash flow turned positive at $6.5M in FY2025 as capital expenditures fell to $1.2M, so the improvement came primarily from reduced reinvestment rather than operating recovery. Operating income was still negative, showing that accounting operations had not yet regained traction.

The balance sheet is tightening: current ratio was 1.0x and current liabilities nearly matched current assets, leaving little short-term cushion. Total liabilities reached $137.8M against $50.0M of equity, while shares outstanding rose to 397.9M shares, making financing structure increasingly important to the operating model.

Financial Health Signals

Financial health score not available

MARIMED INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-0.04

MARIMED INC scores -0.04, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($23.0M) relative to total liabilities ($137.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

MARIMED INC passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

N/A

MARIMED INC reported a net loss of $14.5M while generating $7.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

MARIMED INC reported an operating loss of $2.8M against $7.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$41.9M

YoY+6.1%

QoQ+6.2%

5Y CAGR+5.2%

10Y CAGR+51.7%

MARIMED INC generated $41.9M in revenue in Q2 2026. This represents an increase of 6.1% from the same quarter a year earlier. Against the prior quarter it is up 6.2%.

EBITDA

$3.9M

YoY-10.8%

QoQ+72.3%

5Y CAGR-20.7%

MARIMED INC's EBITDA was $3.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 10.8% from the same quarter a year earlier. Against the prior quarter it is up 72.3%.

Net Income

-$3.6M

YoY-157.5%

QoQ+5.2%

MARIMED INC reported -$3.6M in net income in Q2 2026. This represents a decrease of 157.5% from the same quarter a year earlier. Against the prior quarter it is up 5.2%.

EPS (Diluted)

-$0.01

QoQ0.0%

MARIMED INC earned -$0.01 per diluted share (EPS) in Q2 2026. It is unchanged from the prior quarter.

Cash & Balance Sheet

Free Cash Flow

$1.9M

YoY+16108.3%

QoQ+233.5%

5Y CAGR-17.9%

MARIMED INC generated $1.9M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 16108.3% from the same quarter a year earlier. Against the prior quarter it is up 233.5%.

Cash & Debt

$8.4M

YoY+37.5%

QoQ+6.3%

5Y CAGR-13.4%

10Y CAGR+37.5%

MARIMED INC held $8.4M in cash against $82.7M in long-term debt as of Q2 2026.

Shares Outstanding

403M

YoY+2.7%

QoQ+0.9%

5Y CAGR+4.1%

10Y CAGR+20.2%

MARIMED INC had 403M shares outstanding in Q2 2026. This represents an increase of 2.7% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

38.7%

YoY-1.6pp

QoQ0.0pp

5Y change-20.9pp

10Y change-28.1pp

MARIMED INC's gross margin was 38.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.6 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.

Operating Margin

1.0%

YoY-1.6pp

QoQ+0.7pp

5Y change-35.9pp

10Y change-14.2pp

MARIMED INC's operating margin was 1.0% in Q2 2026, reflecting core business profitability. This is down 1.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.7 percentage points.

Net Margin

-8.6%

YoY-5.0pp

QoQ+1.0pp

5Y change-31.6pp

10Y change-0.7pp

MARIMED INC's net profit margin was -8.6% in Q2 2026, showing the share of revenue converted to profit. This is down 5.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.0 percentage points.

Return on Equity

-8.3%

YoY-5.9pp

QoQ-0.2pp

5Y change-38.6pp

MARIMED INC's ROE was -8.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 5.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.

Capital Allocation

Capital Expenditures

$298K

YoY-3.6%

QoQ-20.1%

5Y CAGR-44.5%

MARIMED INC invested $298K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 3.6% from the same quarter a year earlier. Against the prior quarter it is down 20.1%.

R&D Spending

Not reported for Q2 2026.

Share Buybacks

Not reported for Q2 2026.

MRMD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MRMD quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$163.8M	$159.8M+1.3%	$157.7M+6.1%	$148.6M+10.9%	$134.0M+10.3%	$121.5M+138.7%	$50.9M+11.6%	$45.6M+284.8%	$11.9M+95.3%	$6.1M+70.2%	$3.6M+180.6%	$1.3M+1337.1%	$88K+9677.0%	$904+15.2%	$785-99.4%	$126K
Cost of Revenue	$105.5M	$101.9M+7.2%	$95.1M+15.0%	$82.7M+18.0%	$70.1M+26.9%	$55.2M+182.1%	$19.6M-27.3%	$26.9M+565.7%	$4.0M+84.3%	$2.2M+62.2%	$1.4M-13.7%	$1.6M+723.9%	$190K+623.5%	$26K+31.8%	$20K-13.4%	$23K
Gross Profit	$58.4M	$57.9M-7.6%	$62.6M-5.0%	$65.9M+3.1%	$64.0M-3.5%	$66.3M+111.5%	$31.3M+67.5%	$18.7M+139.4%	$7.8M+101.6%	$3.9M+99.1%	$1.9M+756.2%	-$297K-191.5%	-$102K-301.0%	-$25K-32.4%	-$19K-118.7%	$103K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$93K	N/A	N/A	N/A	N/A
SG&A Expenses	$27.3M	$26.1M+2.0%	$25.6M+15.8%	$22.1M+6.7%	$20.7M-24.8%	$27.6M+178.4%	$9.9M+12.3%	$8.8M-12.3%	$10.1M+249.0%	$2.9M+273.8%	$770K+35.7%	$568K+87.9%	$302K+147.7%	$122K-33.8%	$184K-2.2%	$188K
Operating Income	-$2.4M	-$2.8M-208.1%	$2.6M-81.9%	$14.4M-29.4%	$20.4M-24.2%	$26.9M+84.9%	$14.5M+135.0%	-$41.5M-675.4%	-$5.4M-4295.9%	$128K-83.5%	$775K+145.9%	-$1.7M-106.8%	-$817K-46.4%	-$558K	N/A	-$374K
EBITDA	N/A	$5.3M-49.7%	$10.5M-47.2%	$19.9M-16.2%	$23.8M-19.8%	$29.7M+81.8%	$16.3M+140.3%	-$40.5M-762.7%	-$4.7M-1057.5%	$491K-52.9%	$1.0M+314.8%	-$485K	N/A	N/A	N/A	N/A
Interest Expense	$8.0M	$7.5M+8.0%	$6.9M-24.4%	$9.2M+442.5%	$1.7M-28.1%	$2.4M-76.0%	$9.8M-22.9%	$12.7M+191.3%	$4.4M+637.0%	$592K+303.7%	-$291K-40.8%	-$207K-267.5%	-$56K	N/A	N/A	N/A
Income Tax	$4.7M	$3.6M-56.0%	$8.2M-13.3%	$9.4M+59.7%	$5.9M-63.6%	$16.2M+683.3%	$2.1M+2977.9%	$67K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$15.0M	-$14.5M-16.2%	-$12.5M+22.2%	-$16.0M-219.0%	$13.5M+86.4%	$7.2M+237.0%	$2.1M+102.6%	-$81.2M-496.8%	-$13.6M-1039.3%	-$1.2M-500.5%	-$199K+89.2%	-$1.8M+75.1%	-$7.4M-1285.6%	-$536K	N/A	-$377K
EPS (Basic)	N/A	-$0.04-33.3%	-$0.03+25.0%	-$0.04-200.0%	$0.04+100.0%	$0.02+100.0%	$0.01+102.6%	-$0.39	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.04	-$0.04-33.3%	-$0.03+25.0%	-$0.04-200.0%	$0.04+100.0%	$0.02	$0.01+102.6%	-$0.39	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	390M+2.9%	379M+4.3%	363M-4.4%	380M+2.1%	372M	324M+55.3%	209M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$41.9M+6.1%	$39.5M+4.2%	$41.6M+7.5%	$40.8M+0.4%	$39.5M-2.3%	$37.9M-0.1%	$38.7M-0.4%	$40.6M+4.6%
Cost of Revenue	$25.7M+9.0%	$24.2M+6.1%	$31.1M+18.5%	$24.4M+2.5%	$23.6M+0.2%	$22.8M+6.3%	$26.3M+21.8%	$23.8M+8.4%
Gross Profit	$16.2M+1.9%	$15.3M+1.2%	$10.5M-15.6%	$16.4M-2.5%	$15.9M-5.8%	$15.1M-8.4%	$12.4M-28.1%	$16.8M-0.3%
SG&A Expenses	$6.9M+8.2%	$6.9M+10.2%	$7.0M+5.8%	$6.6M+8.1%	$6.3M-6.8%	$6.3M+1.8%	$6.6M-0.6%	$6.1M-0.6%
Operating Income	$418K-58.9%	$125K+113.7%	-$4.5M-164.2%	$1.6M+18.9%	$1.0M+6.3%	-$910K-145.0%	-$1.7M-171.0%	$1.3M-59.1%
EBITDA	$3.9M-10.8%	$2.3M+154.0%	-$4.8M-192.5%	$4.7M+12.3%	$4.4M+11.1%	$897K-77.3%	-$1.6M-173.9%	$4.2M-28.7%
Interest Expense	$2.0M+13.9%	$2.0M+12.1%	$2.2M+14.2%	$1.8M+7.0%	$1.8M+2.2%	$1.8M+8.2%	$1.9M+21.1%	$1.7M-31.3%
Income Tax	$2.0M+192.0%	$2.7M-6.4%	-$2.7M-154.3%	$2.8M+321.2%	$691K-20.2%	$2.8M+67.5%	$4.9M+872.1%	$655K-85.3%
Net Income	-$3.6M-157.5%	-$3.8M+31.3%	-$4.6M+45.6%	-$2.9M-193.0%	-$1.4M+15.6%	-$5.5M-324.6%	-$8.5M+16.3%	-$1.0M+76.4%
EPS (Basic)	-$0.01	-$0.010.0%	-$0.01+50.0%	-$0.01	$0.00	-$0.01	-$0.020.0%	$0.00+100.0%
EPS (Diluted)	-$0.01	-$0.010.0%	-$0.01+50.0%	-$0.01	$0.00	-$0.01	-$0.020.0%	$0.00+100.0%
Diluted Shares (Avg)	400M+2.5%	397M+3.9%	N/A	393M+3.2%	390M+2.7%	383M+2.0%	N/A	381M+2.0%

Not reported in any period shown, so not listed: R&D Expenses.

MRMD Balance Sheet

MRMD quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$202.6M-2.1%	$207.0M+5.5%	$196.1M+28.9%	$152.2M+23.5%	$123.2M+61.2%	$76.4M+24.2%	$61.6M-25.8%	$83.0M+157.6%	$32.2M+276.1%	$8.6M+130.3%	$3.7M+125.0%	$1.7M0.0%	$1.7M+1256.2%	$122K-35.9%	$190K
Current Assets	$59.3M+10.8%	$53.5M+4.0%	$51.4M+16.5%	$44.1M-1.0%	$44.6M+112.0%	$21.0M+185.3%	$7.4M-53.0%	$15.7M+216.1%	$5.0M+103.8%	$2.4M+156.8%	$949K-26.8%	$1.3M+17.6%	$1.1M+804.4%	$122K-35.9%	$190K
Cash & Equivalents	$8.9M+22.0%	$7.3M-50.3%	$14.6M+50.4%	$9.7M-67.2%	$29.7M+889.7%	$3.0M+306.0%	$739K-82.0%	$4.1M+218.1%	$1.3M+126.6%	$569K+253.9%	$161K-83.7%	$988K+11474.9%	$9K-0.5%	$9K-92.8%	$119K
Short-Term Investments	$0	$0-100.0%	$88K-28.5%	$123K-51.0%	$251K-81.5%	$1.4M-6.3%	$1.4M	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$36.6M+9.3%	$33.5M+32.3%	$25.3M+29.9%	$19.5M+99.4%	$9.8M+43.0%	$6.8M+460.1%	$1.2M+1248.0%	$90K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$9.1M+4.3%	$8.7M+21.4%	$7.2M+73.2%	$4.2M+149.5%	$1.7M-75.0%	$6.7M+299.9%	$1.7M-69.0%	$5.4M+269.9%	$1.5M+172.9%	$533K+177.0%	$192K+283.9%	$50K0.0%	$50K	N/A	N/A
Long-Term Investments	$0	$0-100.0%	$221K	$0	$0-100.0%	$1.2M-12.0%	$1.3M-20.8%	$1.7M	$0	$0	$0	$0	$0	$0	$0
Goodwill	$24.0M+51.8%	$15.8M+31.8%	$12.0M+48.4%	$8.1M+290.7%	$2.1M0.0%	$2.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$137.8M+6.5%	$129.4M+20.7%	$107.2M+13.0%	$94.9M+9.2%	$86.9M+62.1%	$53.6M-2.9%	$55.2M+160.6%	$21.2M0.0%	$21.2M+132.5%	$9.1M+61.3%	$5.6M+57.8%	$3.6M+34.3%	$2.7M+319.3%	$636K+82.3%	$349K
Current Liabilities	$59.1M+18.1%	$50.0M+62.0%	$30.9M+16.5%	$26.5M-2.7%	$27.2M+17.2%	$23.2M-36.7%	$36.7M+269.0%	$10.0M-35.5%	$15.4M+151.9%	$6.1M+8.4%	$5.6M+269.1%	$1.5M0.0%	$1.5M+140.8%	$636K+82.3%	$349K
Non-Current Liabilities	$78.8M-0.8%	$79.4M+4.0%	$76.3M+11.6%	$68.4M+14.6%	$59.7M+96.4%	$30.4M+64.1%	$18.5M+64.7%	$11.2M+94.8%	$5.8M+92.9%	$3.0M	$0-100.0%	$2.0M+80.7%	$1.1M	$0	$0
Long-Term Debt	$76.0M-2.7%	$78.2M	N/A	N/A	N/A	$36.7M+1.2%	$36.3M+67.4%	$21.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$50.0M-14.6%	$58.5M-15.0%	$68.9M+20.2%	$57.3M+57.9%	$36.3M+348.1%	$8.1M+28.0%	$6.3M-89.8%	$61.8M+461.1%	$11.0M+2096.1%	-$551K+71.5%	-$1.9M-0.2%	-$1.9M-90.4%	-$1.0M-97.1%	-$514K-223.8%	-$159K
Retained Earnings	-$127.9M-12.8%	-$113.4M-13.5%	-$100.0M-19.1%	-$83.9M+13.8%	-$97.4M+6.9%	-$104.6M+2.0%	-$106.8M-317.4%	-$25.6M-113.6%	-$12.0M-11.1%	-$10.8M-5.7%	-$10.2M-13.6%	-$9.0M0.0%	-$9.0M-641.0%	-$1.2M-220.8%	-$377K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$197.2M-3.5%	$201.2M-3.3%	$202.6M-2.1%	$205.6M-3.3%	$204.4M-2.0%	$208.0M+3.3%	$207.0M+5.5%	$212.7M+11.5%
Current Assets	$58.4M+2.3%	$60.8M+4.8%	$59.3M+10.8%	$60.1M+6.0%	$57.1M+7.7%	$58.0M+5.7%	$53.5M+4.0%	$56.7M+11.6%
Cash & Equivalents	$8.4M+37.5%	$7.9M+10.2%	$8.9M+22.0%	$6.6M-32.6%	$6.1M-39.8%	$7.2M-52.7%	$7.3M-50.3%	$9.8M-26.2%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0-100.0%	$0-100.0%
Inventory	$36.7M-5.5%	$39.3M+4.6%	$36.6M+9.3%	$40.0M+14.5%	$38.8M+24.7%	$37.6M+29.3%	$33.5M+32.3%	$35.0M+44.5%
Accounts Receivable	$9.4M+21.7%	$9.4M+2.8%	$9.1M+4.3%	$8.0M+8.7%	$7.7M-0.7%	$9.2M+41.5%	$8.7M+21.4%	$7.3M+15.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%
Goodwill	$24.0M+19.7%	$24.0M+23.2%	$24.0M+51.8%	$22.7M+43.3%	$20.1M+26.8%	$19.5M+23.2%	$15.8M+31.8%	$15.8M+31.8%
Total Liabilities	$147.1M+12.1%	$147.7M+10.2%	$137.8M+6.5%	$136.6M+8.5%	$131.2M+8.5%	$134.1M+18.1%	$129.4M+20.7%	$125.8M+36.8%
Current Liabilities	$63.8M+25.1%	$63.8M+15.3%	$59.1M+18.1%	$56.6M+26.9%	$50.9M+25.3%	$55.3M+56.0%	$50.0M+62.0%	$44.6M+26.4%
Non-Current Liabilities	$83.3M+3.8%	$84.0M+6.6%	$78.8M-0.8%	$80.0M-1.6%	$80.3M0.0%	$78.8M+0.9%	$79.4M+4.0%	$81.2M+43.4%
Long-Term Debt	$82.7M+6.7%	$82.5M+6.7%	$76.0M-2.7%	$76.2M-4.0%	$77.5M-2.5%	$77.4M+0.9%	$78.2M	$79.4M+154.7%
Total Equity	$43.2M-24.0%	$46.5M-19.6%	$50.0M-14.6%	$54.3M-18.4%	$56.9M-15.4%	$57.8M-14.6%	$58.5M-15.0%	$66.6M-16.6%
Retained Earnings	-$135.3M-13.9%	-$131.7M-12.0%	-$127.9M-12.8%	-$123.3M-18.7%	-$118.8M-15.5%	-$117.6M-16.1%	-$113.4M-13.5%	-$103.9M-15.7%

MRMD Cash Flow Statement

MRMD quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$9.3M	$7.7M+13.4%	$6.8M-14.2%	$7.9M+8.2%	$7.3M-79.6%	$35.9M+960.7%	$3.4M+114.0%	-$24.1M-730.1%	-$2.9M-264.8%	$1.8M+991.6%	-$198K+49.6%	-$393K+13.7%	-$455K-4173.2%	-$11K+91.6%	-$127K+29.7%	-$181K
Depreciation & Amortization	N/A	$8.1M+2.5%	$7.9M+42.5%	$5.5M+61.7%	$3.4M+21.7%	$2.8M+56.7%	$1.8M+80.0%	$1.0M+52.0%	$658K+81.3%	$363K+36.6%	$266K-78.0%	$1.2M	N/A	N/A	N/A	N/A
Stock-Based Compensation	N/A	$1.9M+77.1%	$1.1M+2.9%	$1.0M-83.9%	$6.3M	N/A	N/A	N/A	$5.8M+434.3%	$1.1M+559.2%	$164K+256.0%	$46K+27.6%	$36K-61.7%	$94K-42.7%	$164K	$0
Capital Expenditures	$1.3M	$1.2M-90.2%	$12.0M-40.6%	$20.1M+65.8%	$12.1M-32.1%	$17.9M+281.3%	$4.7M-51.5%	$9.7M+8.3%	$8.9M-57.5%	$21.0M+523.5%	$3.4M	N/A	-$3K	N/A	N/A	N/A
Free Cash Flow	$8.0M	$6.5M+226.1%	-$5.2M+57.7%	-$12.2M-153.1%	-$4.8M-126.9%	$18.0M+1475.2%	-$1.3M+96.1%	-$33.8M-185.7%	-$11.8M+38.4%	-$19.2M-439.3%	-$3.6M	N/A	-$458K	N/A	N/A	N/A
Investing Cash Flow	-$2.0M	-$1.4M+91.9%	-$17.1M+34.1%	-$26.0M+1.0%	-$26.2M-57.9%	-$16.6M-272.5%	-$4.5M+64.4%	-$12.5M+68.7%	-$40.1M-91.5%	-$20.9M-526.4%	-$3.3M+4.7%	-$3.5M-823.2%	-$380K-3679.4%	$11K-38.5%	$17K	N/A
Financing Cash Flow	-$5.0M	-$4.7M-257.9%	$3.0M-87.0%	$23.0M+2368.8%	-$1.0M-113.6%	$7.5M+122.9%	$3.3M-90.0%	$33.3M-27.3%	$45.8M+130.4%	$19.9M+403.7%	$3.9M+28.5%	$3.1M+69.2%	$1.8M	N/A	N/A	$300K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$400K-1326.1%	-$28K	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$2.2M+647.1%	$949K-26.6%	$3.4M+930.3%	$2.7M+233.3%	$297K-90.7%	$1.3M-59.7%	-$413K-112.8%	$803K-89.8%
Depreciation & Amortization	$3.5M+3.6%	$2.2M+19.1%	$2.1M-4.1%	$3.1M+9.2%	$3.4M+12.7%	$1.8M-6.8%	$2.2M+26.3%	$2.9M+9.2%
Stock-Based Compensation	N/A	$325K-40.6%	N/A	N/A	N/A	$547K+124.2%	N/A	N/A
Capital Expenditures	$298K-3.6%	$373K+40.2%	$33K-96.9%	$559K-78.2%	$309K-93.8%	$266K-92.1%	$1.1M-80.3%	$2.6M-57.0%
Free Cash Flow	$1.9M+16108.3%	$576K-43.9%	$3.4M+330.9%	$2.1M+220.1%	-$12K+99.3%	$1.0M+750.0%	-$1.5M+31.5%	-$1.8M-191.0%
Investing Cash Flow	-$507K+8.5%	-$753K-554.8%	-$197K+83.6%	-$514K+75.8%	-$554K+94.2%	-$115K+97.3%	-$1.2M+81.1%	-$2.1M+65.8%
Financing Cash Flow	-$1.2M-50.4%	-$1.1M+9.2%	-$944K-5.7%	-$1.7M-285.8%	-$806K-161.2%	-$1.3M-176.5%	-$893K-119.8%	$917K+130.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

MRMD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MRMD quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	36.2%-3.5pp	39.7%-4.7pp	44.4%-3.4pp	47.7%-6.8pp	54.5%-7.0pp	61.6%+20.5pp	41.0%-24.9pp	65.9%+2.0pp	63.9%+9.2pp	54.6%+78.0pp	-23.4%	-115.2%	-2807.6%	-2441.2%	81.7%
Operating Margin	-1.8%-3.4pp	1.7%-8.0pp	9.7%-5.5pp	15.2%-6.9pp	22.1%-6.4pp	28.5%+119.6pp	-91.1%-45.9pp	-45.2%-47.3pp	2.1%-19.7pp	21.8%	-133.1%	-924.8%	-61741.7%	N/A	-297.5%
Net Margin	-9.1%-1.1pp	-7.9%+2.9pp	-10.8%-20.8pp	10.1%+4.1pp	5.9%+1.7pp	4.2%	-178.0%	-114.8%	-19.7%-14.1pp	-5.6%	-145.4%	-8396.6%	-59248.6%	N/A	-300.5%
Return on Equity	-29.0%-7.7pp	-21.3%+2.0pp	-23.3%-46.8pp	23.5%+3.6pp	19.9%-6.6pp	26.5%+1309.4pp	-1282.9%-1260.9pp	-22.0%-11.2pp	-10.8%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-7.1%-1.1pp	-6.0%+2.1pp	-8.2%-17.0pp	8.8%+3.0pp	5.9%+3.1pp	2.8%+134.7pp	-131.8%-115.5pp	-16.4%-12.7pp	-3.7%-1.4pp	-2.3%+47.4pp	-49.7%+399.5pp	-449.2%-416.7pp	-32.4%	N/A	-198.6%
Current Ratio	1.00-0.1x	1.07-0.6x	1.670.0x	1.670.0x	1.64+0.7x	0.91+0.7x	0.20-1.4x	1.58+1.3x	0.32-0.1x	0.40+0.2x	0.17-0.7x	0.85+0.1x	0.72+0.5x	0.19-0.4x	0.55
Debt-to-Equity	1.52+0.2x	1.34-0.2x	1.56-0.1x	1.66-0.7x	2.39-2.1x	4.53-1.2x	5.73+5.4x	0.35-1.6x	1.93	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.790.0x	0.760.0x	0.76-0.1x	0.88-0.1x	0.99+0.3x	0.67-0.1x	0.74+0.6x	0.140.0x	0.19-0.2x	0.42+0.1x	0.34+0.3x	0.05+0.1x	0.000.0x	0.01-0.7x	0.66
FCF Margin	4.1%+7.4pp	-3.3%+4.9pp	-8.2%-4.6pp	-3.6%-18.4pp	14.8%+17.4pp	-2.6%+71.6pp	-74.1%+25.7pp	-99.8%	-316.6%	-99.9%	N/A	-518.1%	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	38.7%-1.6pp	38.7%-1.1pp	25.2%-6.9pp	40.1%-1.2pp	40.3%-1.5pp	39.8%-3.6pp	32.1%-12.4pp	41.3%-2.1pp
Operating Margin	1.0%-1.6pp	0.3%+2.7pp	-10.9%-6.4pp	3.9%+0.6pp	2.6%+0.2pp	-2.4%-7.7pp	-4.4%-10.6pp	3.3%-5.2pp
Net Margin	-8.6%-5.0pp	-9.6%+5.0pp	-11.1%+10.9pp	-7.2%-4.8pp	-3.5%+0.6pp	-14.5%-11.1pp	-22.0%+4.2pp	-2.5%+8.5pp
Return on Equity	-8.3%-5.9pp	-8.1%+1.4pp	-9.3%+5.3pp	-5.4%-3.9pp	-2.5%0.0pp	-9.5%-7.6pp	-14.5%+0.2pp	-1.5%+3.8pp
Return on Assets	-1.8%-1.1pp	-1.9%+0.8pp	-2.3%+1.8pp	-1.4%-1.0pp	-0.7%+0.1pp	-2.6%-2.0pp	-4.1%+1.1pp	-0.5%+1.8pp
Current Ratio	0.92-0.2x	0.95-0.1x	1.00-0.1x	1.06-0.2x	1.12-0.2x	1.05-0.5x	1.07-0.6x	1.27-0.2x
Debt-to-Equity	1.91+0.6x	1.77+0.4x	1.52+0.2x	1.40+0.2x	1.36+0.2x	1.34+0.2x	1.34-0.2x	1.19+0.8x
Asset Turnover	0.210.0x	0.200.0x	0.210.0x	0.200.0x	0.190.0x	0.180.0x	0.190.0x	0.190.0x
FCF Margin	4.6%+4.6pp	1.5%-1.3pp	8.2%+11.9pp	5.2%+9.5pp	0.0%+4.4pp	2.7%+3.1pp	-3.8%+1.7pp	-4.3%-9.3pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
MARIMED INC MRMD	FY2025	$159.8M	-$14.5M	-9.1%	$23.0M	—
THE CANNABIST CO HLDG CBSTF	FY2024	$458.7M	-$105.9M	-23.1%	$14.5M	—
EARTH SCIENCE TECH INC ETST	FY2026	$35.7M	$3.6M	10.2%	$25.4M	—
IANTHUS CAPITAL HLDG ITHUF	FY2025	$144.0M	-$40.2M	-27.9%	$28.6M	—

Where MARIMED INC Ranks

Frequently Asked Questions

What is MARIMED INC's annual revenue?

MARIMED INC (MRMD) reported $159.8M in total revenue for fiscal year 2025. This represents a 1.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is MARIMED INC's revenue growing?

MARIMED INC (MRMD) revenue grew by 1.3% year-over-year, from $157.7M to $159.8M in fiscal year 2025.

Is MARIMED INC profitable?

No, MARIMED INC (MRMD) reported a net income of -$14.5M in fiscal year 2025, with a net profit margin of -9.1%.

What is MARIMED INC's EBITDA?

MARIMED INC (MRMD) had EBITDA of $5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does MARIMED INC have?

As of fiscal year 2025, MARIMED INC (MRMD) had $8.9M in cash and equivalents against $76.0M in long-term debt.

What is MARIMED INC's gross margin?

MARIMED INC (MRMD) had a gross margin of 36.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is MARIMED INC's operating margin?

MARIMED INC (MRMD) had an operating margin of -1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is MARIMED INC's net profit margin?

MARIMED INC (MRMD) had a net profit margin of -9.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is MARIMED INC's return on equity (ROE)?

MARIMED INC (MRMD) has a return on equity of -29.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is MARIMED INC's free cash flow?

MARIMED INC (MRMD) generated $6.5M in free cash flow during fiscal year 2025. This represents a 226.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is MARIMED INC's operating cash flow?

MARIMED INC (MRMD) generated $7.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are MARIMED INC's total assets?

MARIMED INC (MRMD) had $202.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are MARIMED INC's capital expenditures?

MARIMED INC (MRMD) invested $1.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does MARIMED INC have outstanding?

MARIMED INC (MRMD) had 398M shares outstanding as of fiscal year 2025.

What is MARIMED INC's current ratio?

MARIMED INC (MRMD) had a current ratio of 1.00 as of fiscal year 2025, which is considered adequate.

What is MARIMED INC's debt-to-equity ratio?

MARIMED INC (MRMD) had a debt-to-equity ratio of 1.52 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is MARIMED INC's return on assets (ROA)?

MARIMED INC (MRMD) had a return on assets of -7.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is MARIMED INC's P/E ratio?

MARIMED INC (MRMD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $23.0M as of Oct 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is MARIMED INC's price-to-sales ratio?

MARIMED INC (MRMD) trades at 0.1x sales, its market capitalization divided by revenue of $163.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $23.0M as of Oct 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is MARIMED INC's Altman Z-Score?

MARIMED INC (MRMD) has an Altman Z-Score of -0.04, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is MARIMED INC's Piotroski F-Score?

MARIMED INC (MRMD) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are MARIMED INC's earnings high quality?

MARIMED INC (MRMD) reported a net loss of $14.5M while generating $7.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can MARIMED INC cover its interest payments?

MARIMED INC (MRMD) reported an operating loss of $2.8M against $7.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.